The company – led by Mark McKenna, formerly chief executive of Prometheus Bio, which was sold to MSD for $10.8 billion ... Rock Springs Capital, Logos Capital, Woodline, and Acuta Capital ...

Meribel Pharma has established centers of excellence in drug development, lyophilization, and preservative-free multidose ...

MSD has entered an exclusive licence agreement with Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the investigational oral small molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346.

MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeuticsCyprumed will be eligible to receive ...

The pharmaceutical industry has a crucial role in modern healthcare, but it also has a significant environmental footprint. From large-scale solvent use and carbon emissions to water pollution and ...

Looking ahead, this article highlights the key trends expected to shape the regulatory landscape of pharmaceutical manufacturing in 2025. Regulatory agencies—including the U.S. Food and Drug ...

Global drugmakers’ stocks dropped across the board today after U.S. President Donald Trump reiterated plans for a “major” tariff on pharmaceutical imports, threatening an interwoven supply ...